Evaxion A/S to Present Two-Year Phase 2 Data on AI-Designed Personalized Cancer Vaccine EVX-01 at ESMO Congress 2025
Evaxion A/S announced that it will present a comprehensive set of data from its phase 2 clinical trial of the AI-designed personalized cancer vaccine EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025, scheduled to take place in Berlin, Germany, from October 17-21, 2025. The data, which will be delivered in an oral session on October 17, will include two-year clinical efficacy, immunogenicity, and safety results. Specific endpoints to be presented cover best overall response, deepened response/conversion rates, durability of response, and details on the breadth, magnitude, and duration of T-cell response following booster immunization. Safety data will also be discussed. A follow-up webinar featuring trial investigator Dr. Muhammad Adnan Khattak is planned for October 22, 2025, to provide further insights and facilitate a Q&A session.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.